CRISPR

CRISPR1-pparab

ID

ZDB-CRISPR-210726-4

Name

CRISPR1-pparab

Previous Names

None

Target

pparab (1)

Sequence

5' - GGACAGTGCGCTGTTCGTCAGGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "GGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
ecn4	pparab

Expression

Gene expression in Wild Types + CRISPR1-pparab

No data available

Phenotype

Phenotype resulting from CRISPR1-pparab

No data available

Phenotype of all Fish created by or utilizing CRISPR1-pparab

Phenotype	Fish	Conditions	Figures
adipose tissue acox3 expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
liver glycogen decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
liver g6pc1a.2 expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
muscle cpt1b expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
muscle bcat1 expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
gut fasn expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
muscle cpt1aa expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1, Fig. 2 from Li et al., 2020
liver cpt1aa expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1, Fig. 2 from Li et al., 2020
whole organism increased weight, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
muscle glycogen decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
muscle pparab expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
amino acid catabolic process decreased occurrence, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 5 from Li et al., 2020
muscle atf4a expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
liver gys2 expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
liver bcat1 expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
gut triglyceride increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
liver fasn expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
whole organism lipid increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
adipose tissue cpt1aa expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
adipose tissue pparaa expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
liver pfklb expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
liver slc2a2 expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
muscle glud1b expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
palmitic acid catabolic process decreased occurrence, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 5 from Li et al., 2020
liver pparaa expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
liver dgat1a expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
liver pparab expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
adipose tissue pparab expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
liver insrb expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
muscle bcat2 expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
liver triglyceride increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
liver fatty acid beta-oxidation decreased efficacy, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
blood insulin decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
gut dgat1a expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
blood glucose decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
whole organism protein increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
liver cpt1b expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
muscle acox3 expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020
muscle bckdha expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
muscle pfklb expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
aerobic respiration decreased rate, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 2 from Li et al., 2020
liver pklr expression increased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 3 from Li et al., 2020
glucose catabolic process increased occurrence, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 5 from Li et al., 2020
muscle asns expression decreased amount, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 4 from Li et al., 2020
muscle fatty acid beta-oxidation decreased efficacy, abnormal	pparab^ecn4/ecn4	standard conditions	Fig. 1 from Li et al., 2020

Citations